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A B S T R A C T
Objective: We aimed to understand the impact of dopamine receptor D4 (DRD4) polymorphisms on neurode-
generation in patients with dementia. We hypothesized that DRD4 dampened-variants with reduced functional
potency would be associated with greater atrophy in regions with higher receptor density. Given that DRD4 is
concentrated in anterior regions of the limbic and cortical forebrain we anticipated genotype eﬀects in patients
with a more rostral pattern of neurodegeneration.
Methods: 337 subjects, including healthy controls, patients with Alzheimer's disease (AD) and frontotemporal
dementia (FTD) underwent genotyping, structural MRI, and cognitive/behavioral testing. We conducted whole-
brain voxel-based morphometry to examine the relationship between DRD4 genotypes and brain atrophy pat-
terns within and across groups. General linear modeling was used to evaluate relationships between genotype
and cognitive/behavioral measures.
Results: DRD4 dampened-variants predicted gray matter atrophy in disease-speciﬁc regions of FTD in anterior
cingulate, ventromedial prefrontal, orbitofrontal and insular cortices on the right greater than the left. Genotype
predicted greater apathy and repetitive motor disturbance in patients with FTD. These results covaried with
frontoinsular cortical atrophy. Peak atrophy patterned along regions of neuroanatomic vulnerability in FTD-
spectrum disorders. In AD subjects and controls, genotype did not impact gray matter intensity.
Conclusions: We conclude that DRD4 polymorphisms with reduced functional potency exacerbate neuronal in-
jury in sites of higher receptor density, which intersect with syndrome-speciﬁc regions undergoing neurode-
generation in FTD.
1. Introduction
Each neurodegenerative disease exhibits phenotypic diversity with
regard to clinical manifestations and neuroanatomical injury patterns
(Seeley, 2017). Considerable attention has been given to genes related
to the etiopathogenesis of neurodegeneration (Chow et al., 1999;
Goldman et al., 2005), but the genes that impact phenotypic diversity
are poorly understood.
In the ﬁrst investigations of this kind, researchers have identiﬁed
several genes that modify the neuroanatomical phenotype. Gennatas
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et al. (2012) demonstrated that the Val158Met polymorphism in the
catechol-O-methyltransferase (COMT) gene inﬂuences neurodegenera-
tion in a dose-dependent fashion such that COMT polymorphisms as-
sociated with increased synaptic dopamine catabolism predicted focal
atrophy in the ventral tegmental area, ventral striatum, insula, and
ventromedial prefrontal cortex (vmPFC). Functional polymorphisms in
the language-associated FOXP2 gene are associated with decreased
perfusion of the left inferior frontal region and reduced verbal ﬂuency
in frontotemporal dementia (FTD) patients (Padovani et al., 2010).
Dyslexia susceptibility genes, KIAA0319 and CNTNAP2, are associated
with cortical thinning in left frontoinsular sites in FTD (Paternico et al.,
2016). Agosta et al. (2009) showed that the apolipoprotein ε4 (ApoE4)
genotype correlated with worsened atrophy in disease-speciﬁc regions
in both Alzheimer's disease (AD) and FTD. This ﬁnding helped stimulate
studies showing that ApoE4 worsens neurodegeneration in mouse
models of primary tauopathy (Shi et al., 2017). This assortment of
studies suggests that genetic variation is important to understand
neuroanatomical phenotypes in neurodegeneration. In particular,
ﬁndings from Gennatas et al. (2012) suggest that change in metabolic
eﬃciency related to COMT polymorphisms can aggravate cellular stress
and impact neurodegeneration. Interestingly, while COMT functions to
inactivate several neurotransmitters across the brain, Val158Met poly-
morphisms exert a focal pattern of neurodegeneration centered on high-
density sites of dopaminergic activity. It remains uncertain whether
receptor-level bioenergetics within dopamine systems play a role in
neurodegeneration.
The human dopamine receptor D4 (DRD4) gene, located near the
telomere of chromosome 11p in humans, is highly polymorphic with
much of the variation due to the length of a 48-base pair tandem repeat
(VNTR) in exon 3, which encodes the third cytoplasmic loop of the
receptor (Lichter et al., 1993; Wang et al., 2004). Alleles with 2–11
repeats have been described, but the three most common variants (4R,
2R, and 7R alleles) explain over 90% of the population diversity (Ding
et al., 2002). Polymorphisms alter the intracellular loop structure, and
subsequently the downstream neuronal signaling (Asghari et al., 1995;
Oak et al., 2000), while receptor-level dopamine binding proﬁles are
relatively similar across allelic variants (Asghari et al., 1994). 2R and
7R variants lead to blunted second messenger response. Compared to
4R/4R (wild-type) receptor function, dopamine potency to inhibit
cyclic adenosine monophosphate (cAMP) production is decreased by
30–40% in 2R variants and 70–80% in 7R transfected cells (Asghari
et al., 1995). Less is known about the functional potency for other
uncommon variants (e.g. 3R, 5R, 6R, 8R).
DRD4 expression across the brain is variable, with higher receptor
densities in anterior regions of the limbic and cortical forebrain (Lahti
et al., 1998; Matsumoto et al., 1995). This anterior pattern is reﬂected
in the data which demonstrate variation in receptor-level function im-
pacts executive and behavioral regulation (Gatt et al., 2015; Munafò
et al., 2008; Rondou et al., 2010). Here, we questioned whether the
common 2R- and 7R-variants would inﬂuence neurodegeneration, be-
havior, and cognition in a cross-sectional group of aged patients with
and without neurodegenerative disease. Reduced eﬃciency of in-
hibitory second-messenger signaling presumably incites downstream
cellular stress in sites previously vulnerable to neurodegeneration.
Subjects with common allelic variants (2R, 4R, and 7R) were included
for analysis based on a priori hypotheses related to receptor-level ef-
fects of genotype and to minimize the confounding eﬀects of alleles
with unknown downstream neuronal function (Rondou et al., 2010).
We hypothesized that DRD4 dampened-variants (2R and 7R) with re-
duced functional potency would be associated with greater atrophy in
regions with higher DRD4 receptor density, especially in patients with a
more rostral pattern of neurodegeneration.
2. Methods
2.1. Subjects
We queried the University of California San Francisco (UCSF)
Memory and Aging Center database for subjects who had undergone
DRD4 genotyping, brain structural MRI, and cognitive/behavioral
testing. Subjects included were those deemed cognitively normal or
meeting clinical criteria for a diagnosis of dementia based on published
consensus research criteria for AD or an FTD-spectrum disorder
(Armstrong et al., 2013; Gorno-Tempini et al., 2011; Litvan et al., 1996;
McKhann et al., 2011; Neary et al., 1998). FTD-spectrum diagnoses
included behavioral variant frontotemporal dementia (bvFTD), se-
mantic variant primary progressive aphasia (svPPA), non-ﬂuent/
agrammatic variant primary progressive aphasia (nfvPPA), corticobasal
syndrome (CBS), and progressive supranuclear palsy (PSP). Participants
underwent behavioral and cognitive testing within 1 year of neuroi-
maging and clinical diagnoses. Earliest initial evaluations were in-
cluded for all subjects followed longitudinally. Neuropathology was
conﬁrmed in 98 of 207 patients with dementia. Age-matched controls
were free from neuropsychiatric history and did not take psychotropic
medications except for 1 individual who reported using trazodone as
needed for sleep. In dementia patients, there was 1 patient with CBS on
levodopa/carbidopa for treatment of parkinsonian motor symptoms
and 5 patients with bvFTD on scheduled or as-needed anti-psychotics
for varying reasons (1 each on aripiprazole, olanzapine, risperidone,
and 2 on quetiapine). Procedures were approved by the UCSF Com-
mittee on Human Research. All subjects and/or caretakers provided
informed consent prior to study participation. All data was collected
between the years of 2000 to 2017. Demographic information was
compared with unpaired two-tailed t-tests and Pearson χ2 tests.
2.2. Cognitive and behavioral testing
Neuropsychological batteries included in bedside screening proto-
cols have been described in prior publications (see Rosen et al., 2002).
To summarize brieﬂy, global cognitive function was assessed with the
Mini-Mental State Examination (MMSE). Verbal episodic memory was
tested with the California Verbal Learning Test (CVLT) 9-item short
form. Visual episodic memory was measured with 10-min free recall of
the Benson ﬁgure, and ﬁgure copy was utilized for visuospatial as-
sessment. Language evaluation included the 15-item Boston Naming
Test (BNT), phonemic and semantic ﬂuency. Tests of executive function
included digit-span backwards, Stroop testing, and a modiﬁed Trails B
test. Global function and disease severity were assessed by the Clinical
Dementia Rating (CDR) scale and the CDR sum-of-boxes score. Beha-
vioral symptoms were measured by the Neuropsychiatric Inventory
(NPI). Test scores nearest to the date of neuroimaging were included in
the analysis. 188 of 207 patients (90.8%) underwent imaging within 90
days of clinical evaluations and 202 of 207 patients (97.6%) within 6
months (mean= 27.6 days, SD=46.5, interquartile range 2–38).
2.3. DRD4 genotyping
The DRD4 exon 3 VNTR was assayed by polymerase chain reaction
(PCR) testing with the AccuPrime™ Taq High Fidelity DNA Polymerase
kit. The reaction contained a 6-FAM labeled forward primer (/56-FAM/
GCGACTACGTGGTCTACTCG) and a reverse primer (AGGACCCTCATG
GCCTTG), as described in Lichter et al. (1993). PCR reactions were
submitted for fragment analysis on an AB3730XL with a LIZ1200 size
standard. This method is a modiﬁcation of the gel-based assay reported
by Chen et al. (1999). 2R, 4R, and 7R alleles represented 92.4% of all
alleles in our sample, which is similar to known allele frequencies
(Butler and Matthews, 2011; Ding et al., 2002). Allele frequencies and
genotypes by group were compared with Pearson χ2 tests.
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2.4. Image acquisition
Structural brain MRIs were acquired on one of three scanners. 152
subjects were scanned at the San Francisco Veteran's Administration
Hospital on a 1.5-Tesla Magnetom VISION system (Siemens, Iselin, NJ)
using a standard quadrature head coil. A volumetric magnetization
prepared rapid gradient-echo MRI (MPRAGE, TR/TE/TI= 10/4/
300ms) was used to obtain T1-weighted images of the entire brain with
15° ﬂip angle, coronal orientation perpendicular to the double spin-
echo sequence, 1.0× 1.0 mm in-plane resolution and 1.5 mm slab
thickness. Another 85 participants underwent imaging at the UCSF
Neuroscience Imaging Center on a 3-Tesla Siemens (Siemens, Iselin, NJ)
TIM Trio scanner equipped with a 12-channel head coil. T-1 weighted
MPRAGE images were obtained (TR/TE/TI= 2300/2.98/900 ms) with
9° ﬂip angle. The ﬁeld of view was 240×256mm, with 1× 1mm in-
plane resolution and 1mm slice thickness. The remaining 100 scans
were performed at the San Francisco Veteran's Administration Hospital
on a 4-Tesla (Bruker/Siemens; Bruker BioSpin MRI GmbH, Ettlingen,
Germany) MRI system with a birdcage transmit and 8-channel receive
coil. T1-weighted MPRAGE sequences (TR/TE/TI= 2300/3/950ms)
were acquired with 7° ﬂip angle and 1.0×1.0×1.0mm3 resolution.
Scanner type was controlled for in linear models as a nuisance cov-
ariate.
2.5. Image preprocessing
Scans were visually inspected for artifact. 1 subject was excluded for
excessive motion artifact but a subsequent repeat scan was adequate for
inclusion. SPM12 (http://www.ﬁl.ion.ucl.ac.uk/spm/) was utilized for
data preprocessing, which included segmentation into gray matter,
white matter, and CSF and then alignment and normalization to
Montreal Neurological Institute (MNI) space. Modulation and
smoothing with an 8-mm full-width at half-maximum (FWHM)
Gaussian kernel was applied. Total intracranial volume was computed
by SPM12 through an automated estimation process to integrate and
sum voxel values from gray matter, white matter, and CSF.
Preprocessed images were assessed for quality with the check sample
homogeneity function in CAT12 (http://dbm.neuro.uni-jena.de/cat/),
which is an SPM12 extension toolbox. In all preprocessing steps, default
parameters were utilized. The ﬁnal voxel resolution was
1.5 mm×1.5mm×1.5mm (3.375mm3).
2.6. Statistical analysis
Voxel-based morphometry (VBM) was performed with statistical
parametric mapping techniques. Smoothed gray matter maps were
entered into a general linear model with group (control, AD, FTD) as a
factor and genotype as the covariate-of-interest. Genotype was modeled
on a linear, interval scale from 1 to 3 for the 4R, 2R, and 7R groups,
which reﬂected proportional, step-wise loss-of-potency as previously
described (Asghari et al., 1995). The 4R group was deﬁned by the wild-
type (4R/4R genotype). The 2R group was composed of the 2R/4R and
2R/2R genotypes. 4R/7R, 7R/7R, and 2R/7R genotypes deﬁned the 7R
group. Nuisance covariates included age-at-scan, sex, total intracranial
volume (TIV), scanner type, and CDR sum-of-boxes. Absolute threshold
masking was set at 0.1. For comparisons within dementia patients, we
utilized proportional scaling (subject-level global normalization per
image) to control for confounding eﬀects of diﬀering severity in global
atrophy within these heterogeneous dementing illnesses (Ridgway
et al., 2009). Statistical maps were initially examined at a level of
puncorr < 0.001 uncorrected for multiple comparisons. The threshold
for statistical signiﬁcance was set at pFWE-corr < 0.05 after family-wise
error (FWE) correction for multiple comparisons (Nichols and Holmes,
2002). Given that DRD4 receptors are present in varying densities
throughout the brain, then whole-brain VBM was preferred to re-
gionally masked analyses (Callier et al., 2003).
Prior to testing our primary hypotheses about impact of DRD4
dampened function on neurodegeneration, we ﬁrst performed a con-
ﬁrmatory analysis to demonstrate patterns of gray matter atrophy in
patients and controls after controlling for age-at-scan, sex, scanner type,
and TIV. SPM t-tests compared whole-brain gray matter maps of con-
trols vs. AD, controls vs. FTD, and AD vs. FTD. Two models were em-
ployed to test for relationships between genotype and gray matter in-
tensity maps. First, we assessed for the eﬀect of DRD4 genotype across
all subjects controlling for nuisance predictors, including diagnostic
group with dummy variable coding. We tested for eﬀects of poly-
morphisms across all subjects because the impact of DRD4 dampened
function on aging is relatively unknown and because previous ﬁndings
from dopamine system genes (e.g. COMT) showed polymorphism ef-
fects across aged subjects, although results were driven primarily by
dementia patients (Gennatas et al., 2012). To speciﬁcally test our hy-
pothesis that dampened DRD4 function exacerbates neurodegeneration
in patients with a more rostral pattern of atrophy, we modeled diag-
nostic group (e.g. healthy control, AD, FTD) as a categorical variable
and genotype as the covariate-of-interest, which included interaction
eﬀects with diagnostic group. Nuisance covariates were age-at-scan,
sex, TIV, scanner type, and disease severity (e.g., CDR sum-of-boxes).
General linear models were used to evaluate relationships among
DRD4 genotype, neuropsychological performance, and NPI scores in
dementia patients. These analyses were performed in STATA 15.0
(StataCorp LLC). NPI sub-scores were only analyzed when at least 50%
of patients within a diagnostic group had non-zero results. NPI scores
and cognitive scores served as dependent variables in separate regres-
sion models. Cases with missing data were excluded list-wise. In the
models for cognitive and behavioral data, diagnosis (AD or FTD) was a
ﬁxed factor and DRD4 genotype was the covariate-of-interest, which
was modeled in the same fashion as in the imaging analyses. Nuisance
covariates included age-at-scan, sex, TIV, education, and CDR sum-of-
boxes score. P-values< 0.05 were considered signiﬁcant after con-
trolling for multiple comparisons.
The results from primary hypothesis testing led to two second-order
VBM analyses to better understand the relationships between genotype,
behavior, and FTD-spectrum syndromes. Signiﬁcant NPI sub-scores
predicted by DRD4 dampened-variants in FTD were used as covariates-
of-interest in SPM T-contrast tests, which masked ﬁndings by regions
identiﬁed from primary hypothesis testing. In another model, we tested
for interactions between FTD-speciﬁc syndromes and genotype after
controlling for typical nuisance parameters.
3. Results
3.1. Demographic, genetic, behavioral, and cognitive data
Table 1 displays basic demographic and genetic characteristics by
group. Supplemental Table 1 displays genotype and allele frequency data
by group. Patients and controls did not diﬀer by age, education, allele
frequencies or genotype. Dementia patients did not diﬀer in male-to-
female ratio, however the ratios diﬀered between patients and controls,
which were controlled for in all statistical models. Compared to age-
matched controls, patients with dementia were impaired on global
cognitive measures (MMSE) without diﬀerence between patients with
AD versus FTD. FTD patients were more clinically impaired than those
with AD based on CDR scores. Within FTD, DRD4 dampened-variants
were more clinically impaired than wild-types. Given these diﬀerences,
we controlled for disease severity with CDR sum-of-boxes score as
covariate in linear models.
FTD-spectrum diagnoses and demographics are listed in
Supplemental Table 2. 104 FTD patients were composed of: 50 bvFTD, 26
svPPA, 16 CBS, 7 nfvPPA, and 5 PSP. 56 of 104 patients with clinical
FTD syndromes were later conﬁrmed neuropathologically to have
frontotemporal lobar degeneration (FTLD). More speciﬁcally, 26
bvFTD, 13 svPPA, 9 CBS, 5 nfvPPA, and 3 PSP patients were
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pathologically proven to be FTLD. 42 of 103 patients with a clinical
diagnosis of probable AD were later neuropathologically conﬁrmed at
autopsy. No patients with a clinical diagnosis of an FTD-spectrum dis-
order were found to have a non-FTLD primary neuropathological di-
agnosis, and no patients with clinical AD were found to have a non-AD
primary neuropathological diagnosis.
Table 2 demonstrates the NPI scores in AD and FTD patients by
genotype groups. General linear modeling demonstrated worsened NPI
apathy sub-scores were predicted by interaction eﬀect between DRD4
dampened-variants and FTD (t=2.03, p=0.04). There was a trend
toward signiﬁcance with higher NPI repetitive motor disturbance sub-
scores being predicted by interaction eﬀect between DRD4 dampened
function and FTD (t=1.65, p=0.099). Cognitive outcome variables
were not predicted by interaction eﬀects between diagnosis and geno-
type after controlling for multiple comparisons. Supplemental table 4
lists results from the neuropsychological battery.
3.2. Neuroimaging analyses
Fig. 1 shows atrophy patterns for AD compared to controls, FTD
compared to controls, and FTD compared to AD. Patients with AD de-
monstrated greater posterior than anterior brain atrophy with peak
gray matter loss in the posterior cingulate cortex, precuneus, mesial
temporal cortex, and lateral temporoparietal cortex. Patients with FTD
exhibited greater anterior than posterior atrophy with accentuated gray
matter loss in the anterior insula (AI), anterior cingulate cortex (ACC),
anterior and inferior temporal cortex, vmPFC, and orbitofrontal cortex
(OFC). A rostral pattern of atrophy distinguished patients with FTD
compared to AD.
DRD4 dampened function did not predict diﬀerences in gray matter
intensity maps across all subjects when controlling for diagnostic group.
In testing our primary hypothesis that DRD4 dampened-variants pre-
dicted atrophy in patients with a more rostral pattern of neurodegen-
eration, we modeled diagnosis as a factor and assessed for interaction
with genotype. There was signiﬁcant interaction eﬀect between the FTD
group and DRD4 dampened function (7R > 2R > 4R). Fig. 2 displays
statistical parametric maps with regions of decreased gray matter in-
tensity in FTD predicted by interaction eﬀects with genotype. DRD4
dampened-variants predicted atrophy in the right AI, bilateral
(right> left) ventral and dorsal ACC, right vmPFC, and right OFC.
Findings are embedded within the atrophy maps from FTD compared to
controls. Table 3 lists results from Fig. 2 with peak T-values and co-
ordinates in Montreal Neurological Institute (MNI) space. Interaction
eﬀects between genotype and group did not predict diﬀerences in gray
matter intensity maps in AD patients or controls.
To understand the neuroanatomical correlates of behavioral change,
NPI sub-scores for apathy and repetitive motor behavior were included
as covariates-of-interest in separate VBM analyses, which modeled di-
agnostic group as a categorical variable and controlled for all nuisance
parameters. Results were masked by those regions identiﬁed in the
primary analysis (see Fig. 2 and Table 3) with greater atrophy asso-
ciated with DRD4 dampened function. Fig. 3 displays the SPM T-con-
trasts with signiﬁcantly decreased gray matter signal within areas
predicted by DRD4 dampened-function, which correlated with the NPI
sub-scores for apathy and repetitive behavior. Results are overlaid on
regional atrophy in FTD related to worsened apathy and repetitive
behavior irrespective of genotype. Worsened apathy NPI sub-scores in
FTD predicted decreased gray matter intensity within regions asso-
ciated with DRD4 dampened function, including the right AI, right mid-
insula, right OFC, right subgenual and ventral ACC, and left ventral
ACC. The signiﬁcant right insular cluster contained 516 voxels with a
peak T-value of 5.16 in the right inferior AI at MNI-coordinates 30/21/
−15. The right OFC cluster contained 1418 voxels with peak T-value of
4.59 at MNI-coordinates 8/32/−27. A smaller cluster of 206 voxels was
identiﬁed in the left ventral ACC with peak T-value of 4.12 at −8/45/
Table 1
Subject characteristics
Control AD FTD
4R/4R 2R+7R 4R/4R 2R+7R 4R/4R 2R+7R
Subjects, N 85 45 64 39 65 39
Age-at-scan 64.5 (9.4) 64.6 (9.4) 65.6 (10.3) 66.2 (10.9) 62.9 (9.2) 62.0 (8.7)
Sex, M:F 31:54†⁎ 13:32†⁎ 38:26† 22:17† 38:27⁎‡ 15:24⁎‡
Education 16.9 (2.5) 16.8 (2.0) 16.0 (3.3) 15.9 (3.2) 15.2 (3.1) 15.6 (2.8)
Illness Duration – – 4.8 (2.3) 4.6 (2.1) 5.4 (4.3) 5.1 (2.9)
CDR, Total – – 0.9 (0.5)ⱡ 0.9 (0.4)ⱡ 0.9 (0.7)ⱡ∂ 1.3 (0.7)ⱡ∂
CDR, sum-of-boxes – – 4.6 (3.2)ⱡ 4.8 (2.2)ⱡ 5.2 (3.6)ⱡ∂ 6.8 (3.7)ⱡ∂
MMSE (max=30) 29.3 (0.8)◊ 29.6 (0.6)◊ 21.8 (6.6)◊ 21.8 (6.1)◊ 23.5 (6.8)◊ 22.6 (6.6)◊
Allele Frequency, % 71.2 16.9+11.9 70.4 16.5+ 13.1 70.0 18.0+ 12.0
Abbreviations: CDR= clinical dementia scale, MMSE=Mini-Mental State Exam, M=male, F= female, AD=Alzheimer's disease, FTD= frontotemporal dementia.
Age-at-scan, education, and illness duration are listed in years.
Statistically signiﬁcant comparisons: There was a signiﬁcant diﬀerence in male-to-female ratios in controls compared to AD (χ2= 13.9, p=0.0002†) and FTD
(χ2= 6.9, p=0.008⁎). Within the FTD group males-to-female ratios diﬀered between 4R/4R wild-and those with 2R and 7R (χ2= 3.90, p=0.048‡). AD (t=14.2,
p=0.0001) and FTD (t=11.0, p=0.0001◊) patients were signiﬁcantly impaired on MMSE testing compared to controls. FTD compared to AD patients were more
impaired based on the CDR (t=2.36, p=0.02) and CDR sum-of-boxes score (t=2.38, p=0.02ⱡ). Within the FTD group the 2R and 7R group were more clinically
impaired on CDR (t=2.82, p=0.006∂) and CDR sum-of-boxes (t=2.17, p=0.03) compared to the wild-type 4R/4R.
Statistically insigniﬁcant comparisons: Subjects did not diﬀer by group in age or education (ps > 0.05), genotype (χ2= 5.18, p=0.74) allele frequencies
(χ2= 0.102, p=0.99), or by genotype grouping (e.g., 4R vs 2R vs 7R groups, χ2= 1.36, p=0.85). AD and FTD subjects did not diﬀer by illness duration (t=1.37,
p=0.17), MMSE scores (ps > 0.1), and male-to-female ratios (χ2= 1.11, p=0.29).
Table 2
NPI scores in dementia patients by DRD4 genotype.
NPI Scores Alzheimer's Dementia Frontotemporal Dementia
4R 2R 7R 4R 2R 7R
Apathy 3.92
(4.1)
4.3 (3.6) 2.8 (3.1) 5.5 (4.4) 7.4 (3.7)
⁎⁎
7.5 (4.8)⁎⁎
Eating 1.6 (2.5) 1.8 (3.3) 2.6 (3.0) 4.4 (4.5) 5.1 (4.3) 5.0 (3.8)
Disinhibition 1.8 (3.8) 1.3 (2.4) 0.5 (1.2) 4.2 (4.3) 2.6 (2.6) 4.9 (4.6)
Irritability 2.2 (3.0) 2.3 (2.8) 1.9 (3.0) 2.2 (3.4) 2.6 (2.6) 2.0 (3.8)
Motor 1.9 (3.4) 1.2 (2.1) 1.5 (3.4) 3.8 (4.5) 7.1
(4.4)⁎
5.9 (5.4)⁎
NPI Total 19.8
(17.8)
18.4
(21.4)
18.3
(16.0)
28.8
(22.0)
38.8
(15.5)
40.7 (29.6)
⁎⁎ Denotes statistical signiﬁcance with p < 0.05
⁎ denotes a trend toward signiﬁcance with p < 0.10. The relationship to NPI
Total score was not signiﬁcant (t=1.47, p=0.14). Other sub-scores examined
were non-signiﬁcant (p > 0.2).
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15 in MNI-space. Worsened NPI sub-scores for repetitive motor beha-
vior in FTD predicted decreased gray matter intensity within regions
associated with DRD4 dampened function, including the right insula
and ventral ACC. Within the right insula there were 530 voxels with
peak T-value of 5.56 in the right mid-insula with MNI-coordinates 34/
10/−4. The right ventral ACC showed a signiﬁcant cluster of 665
voxels peak T-value of 4.06 at 8/46/2 in MNI-space.
To evaluate possible syndrome-speciﬁc eﬀects, FTD-spectrum di-
agnoses of bvFTD (N=50) and svPPA (N=26) were coded as distinct
groups in the categorical variable for diagnosis in SPM modeling. The
other FTD syndrome groups were underpowered to detect meaningful
group-level diﬀerences by genotype and were subsequently excluded
from this analysis. We performed whole-brain gray matter contrasts by
group with genotype as the covariate-of-interest and controlled for
nuisance parameters as before. Fig. 4 displays the syndrome-speciﬁc
atrophy eﬀects of DRD4 polymorphisms within bvFTD and svPPA.
Table 4 lists the MNI-coordinates and neuroanatomical regions of de-
creased gray matter intensity that covaried with DRD4 polymorphisms
in bvFTD and svPPA. In bvFTD, there was notable decrease in right
anterior and mid-insula, right ventral ACC/OFC, and right anterior and
inferior temporal sites. In svPPA, DRD4 dampened-variants predicted
atrophy in bilateral superior dorsolateral PFC, dorsomedial prefrontal
cortex (dmPFC), and bilateral dorsal ACC/vmPFC.
Fig. 1. Global atrophy patterns between dementia patients and age-matched controls.
VBM analyses controlling for age, sex, scanner type, and total intracranial volume conﬁrmed the AD and FTD diagnostic groups exhibited atrophy patterns that were
consistent with their clinical syndromes. Statistical parametric maps were corrected at pFWE-corr < 0.05. N=337. Results are displayed on a coronal MNI slice-
labeled average template brain.
Fig. 2. Regions where DRD4 dampened function is associated with greater atrophy in FTD with results nested in FTD versus control atrophy maps.
Interaction eﬀect by group and genotype showed signiﬁcant clusters of decreased gray matter intensity in FTD patients predicted by DRD4 dampened-variants. VBM
analyses controlled for age, sex, scanner type, total intracranial volume, and disease severity (CDR sum-of-boxes). Corrected statistical parametric maps are displayed
at pFWE-corr < 0.05. Signiﬁcant results are displayed with the orange/red heat map and embedded in larger regional atrophy maps from FTD compared to controls,
which is displayed with the blue/green color map. Slices are labeled with MNI coordinates. Results are overlaid on an MNI average template brain. Interaction eﬀects
by genotype and group in AD and controls were not signiﬁcant predictors of gray matter intensity change. Table 3 lists the MNI coordinates of signiﬁcant voxels/
clusters in FTD predicted by interaction eﬀects with DRD4 dampened-variants.
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4. Discussion
The substantial anatomical and clinical heterogeneity within de-
mentia syndromes inﬂuences diagnostic certainty and prognosis (Perry
et al., 2017). Identifying sources of patient-level variation is important
to clarify disease mechanisms and suggest possible targets for patient-
tailored disease-modifying therapies. Building on previous ﬁndings
(Agosta et al., 2009; Gennatas et al., 2012; Padovani et al., 2010) the
present research supports the hypothesis that an individual's back-
ground genetic constitution impacts the manifestation of neurodegen-
erative illness. Beyond disease susceptibility eﬀects, genotype can shape
the spatial landscape of degeneration and associated cognitive and
behavioral proﬁles.
Previous work demonstrates that DRD4 dampened-variants exhibit
linearly reduced receptor-level potency in second-messenger response
(Asghari et al., 1995). In the present study, we asked whether these
variants known to impact downstream signaling ﬁdelity might exacer-
bate neuronal injury in regions of high-receptor density. Results sup-
ported our hypothesis, as DRD4 dampened-variants displayed accen-
tuated atrophy in the right AI, dorsal and ventral ACC, vmPFC, and
OFC. Rostral cortical degeneration, rather than posterior or striatal, was
predicted by genotype in patients with FTD.
DRD4 dampened-variants with FTD exhibited greater behavioral
apathy. Worsened NPI apathy sub-scores covaried with decreased gray
matter signals predicted by DRD4 dampened-function in the right
anterior-inferior insula, right OFC, and right greater than left ventral
ACC. While repetitive motor behavior only demonstrated a trend to-
ward signiﬁcance in general linear modeling of NPI sub-scores, the SPM
T-map contrasts showed signiﬁcant patterns of signal change predicted
by DRD4 dampened function in FTD subjects in the right AI, mid-insula
and ventral ACC. In terms of overall clinical severity, patients with FTD
in the 2R and 7R groups compared to the 4R wild-type group were more
clinically impaired based on CDR scores. This potential confound could
be due to chance variation in our cross-sectional sample (e.g. ascer-
tainment bias) or it could reﬂect DRD4-mediated eﬀects. To control for
this possible confound, measures of clinical severity were used as pre-
dictors in linear models.
We evaluated the correlates of DRD4 polymorphisms within bvFTD
and svPPA, the two FTD syndromes with suﬃcient sample size to detect
syndrome-speciﬁc patterns. Atrophy was intensiﬁed in right ventral
frontotemporal structures in bvFTD and bilateral dorsal frontal sites in
svPPA. More speciﬁcally, in bvFTD DRD4 dampened-variants predicted
gray matter density loss in right AI, mid-insula, right inferior and
anterior temporal cortex, and right ventral ACC/OFC. In svPPA, poly-
morphisms correlated with bilateral superior frontal, dmPFC and
vmPFC/ACC. In bvFTD, DRD4-associated atrophy within the right in-
sula nested within well-described foci of atrophy. In svPPA, on the other
hand, atrophy involved syndrome-related sites but not the peak hubs of
atrophy (e.g. left anterior/inferior temporal cortex). Taken together,
regionally aggravated degeneration in FTD patients under the inﬂuence
of potency-reducing DRD4 polymorphisms overlapped with key nodes
of the salience network (Seeley et al., 2007). This large-scale brain
network is selectively vulnerable in FTD, and has been shown to be
involved in various forms of salience processing that modulate emo-
tions, reward and homeostatic regulation (Guo et al., 2016; Seeley
et al., 2009; Sturm et al., 2013). The localization of D4 receptors to
limbic and cortical systems of the anterior more than posterior fore-
brain might explain why patients with FTD but not AD dementia were
susceptible to aggravated neurodegeneration in these regions. In other
words, the neuronal milieu may be threatened most in regions of
neuroanatomical overlap between typical sites of neurodegeneration
and circuits richly innervated by D4 receptors. FTD-spectrum disorders
are associated with hypo-dopaminergic states (Huey et al., 2006),
which taken together with DRD4 dampened function might expose these
rostral circuits to dysregulation thereby hastening degeneration.
How molecular pathophysiology translates into local and large-scale
network degeneration remains unclear (Raj et al., 2012; Seeley et al.,
2009; Warren et al., 2013; Zhou et al., 2012). Elucidating mechanistic
links between DRD4 circuit function and FTD-speciﬁc proteinopathies
(e.g. TDP-43, tau) will be important for understanding how DRD4
dampened-variants inﬂuence neurodegeneration. We tested the
Table 3
Decreased gray matter intensity signals in FTD predicted by interaction eﬀects
between diagnostic group and DRD4 polymorphisms with dampened function.
Anatomic region MNI Coordinates Peak T-
value
Cluster Size
X Y Z
Right ventral ACC/vmPFC 10 44 10 5.24
Right dorsal ACC/dmPFC 8 28 28 4.60 2178
Right ventral ACC/medial
OFC
4 42 −20 4.29
Right anterior insula 27 22 −15 4.51
Right lateral OFC 42 27 2 4.19 720
Right mid-insula 38 −4 9 3.87
Left ventral ACC −8 45 16 4.45 299
Abbreviations: MNI=Montreal Neurologic Institute coordinate space,
ACC= anterior cingulate cortex, vmPFC= ventromedial prefrontal cortex,
dmPFC=dorsal medial prefrontal cortex, OFC=orbitofrontal cortex. Cluster
size is listed at the voxel-level (voxel size is 1.5 mm3). Results are signiﬁcant at
pFWE-corr < 0.05.
Fig. 3. Regional atrophy in FTD correlated with worsened apathy and repetitive
motor behavior which covaried with decreased gray matter signal predicted by
DRD4 dampened function.
Statistical parametric maps of signiﬁcantly decreased gray matter intensities
which were predicted by interaction eﬀect between FTD group and NPI apathy
and repetitive motor sub-scores. Results were masked by regions of atrophy
related to DRD4 dampened function. Results are displayed at pFWE-corr < 0.05
with red/purple heat maps embedded in blue maps which denote regions of
signiﬁcant atrophy related to worsened apathy and repetitive motor behavior in
all patients with FTD. Results are overlaid on an MNI average template brain.
Coronal slices are labeled with MNI coordinates.
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hypothesis that decreased receptor eﬃciency (7R > 2R > 4R) in
terms of second-messenger response to dopaminergic binding might
mediate these eﬀects. Even though modeled results of decreased re-
gional gray matter intensity linearly covaried with D4 dampened-var-
iants in the expected fashion, the results might be driven by other
mechanisms. The eﬀects of D4 receptor variants is not limited to the
primary eﬀects of functional potency of G-protein mediated cAMP re-
sponse and might include release of inﬂammatory mediators (e.g. ara-
chidonic acid), modulation of ion-channel currents, direct eﬀects from
SH3-domain binding, altered mRNA expression, altered receptor di-
merization, antagonistic eﬀects from other catecholamine systems, or
dysregulation of corticostriatal glutamatergic projections (Mei et al.,
1995; Oldenhof et al., 1998; Piomelli et al., 1991; Rondou et al., 2010;
Tarazi and Baldessarini, 1999). The present ﬁndings raise the question
of whether interaction eﬀects might be present between DRD4 dam-
pened-variants and COMT Val158Met polymorphisms (Gennatas et al.,
2012) in patients with dementia. Insuﬃcient shared samples sizes
precluded the possibility of probing for these interactions. Future in-
vestigations with bolstered sample sizes might consider interaction ef-
fects between polymorphic dopamine system genes, relationship be-
tween DRD4-dampened function and familial forms of FTD (e.g. MAPT),
and inﬂuence of polymorphisms on atypical parkinsonian disorders.
Clarifying the mechanisms whereby D4 variants inﬂuence neuro-
degeneration is important when considering possible targets for pa-
tient-centered disease-modifying therapies. Studies investigating neu-
ronal response to D4-selective pharmacologic agents (e.g. agonist/
antagonists) suggest there may be diﬀerential response in non-wild
types (van Van Tol et al., 1992). Preferential localization of D4 re-
ceptors in limbic/cortical more than striatal sites makes this target at-
tractive for development of novel psychopharmacologic agents since
animal models suggest decreased risk of extrapyramidal side eﬀects
(Yan et al., 2012).
Small sample sizes within several FTD-spectrum disorders (e.g.
nfvPPA) limited the present study's ability to understand the inﬂuence
of DRD4 polymorphisms on neurodegeneration within varying FTD
clinical syndromes. Additionally, sample size may have been in-
suﬃcient to detect small diﬀerences in cognitive measures within pa-
tient groups based on genotype. Behavioral correlates of DRD4-dam-
pened function in patients with FTD-spectrum disorders deserve further
exploration with reward-processing and decision-making paradigms.
Speciﬁc mechanistic hypotheses could be tested given DRD4 expression
is high in frontal and insular cortices and relatively low in the shell of
the nucleus accumbens (Svingos et al., 2000).
5. Conclusions
This study provides evidence that non-wild type DRD4 polymorph-
isms associated with blunted neuronal signaling predict decreased gray
matter signal intensities in FTD within receptor-dense regions. Future
studies should aim to understand longitudinal neuroanatomical and
behavioral eﬀects, network-based correlates, and possible serum or
spinal ﬂuid markers of neuronal injury. The human ﬁndings reported
here could also serve as motivation for exploring the inﬂuence of ma-
nipulating dopamine signaling on FTD-related neurodegeneration in
model organisms.
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